AKT Inhibitors Promote Cell Death in Cervical Cancer Through Disruption of MTOR Signaling and Glucose Uptake

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Apr 8

PMID 24705275

Citations 43

Authors

Ramachandran Rashmi

Carl DeSelm

Cynthia Helms

Anne Bowcock

Buck E Rogers

Janet L Rader

Janet Rader

Perry W Grigsby

Julie K Schwarz

Affiliations

Soon will be listed here.

Abstract

Background: PI3K/AKT pathway alterations are associated with incomplete response to chemoradiation in human cervical cancer. This study was performed to test for mutations in the PI3K pathway and to evaluate the effects of AKT inhibitors on glucose uptake and cell viability.

Experimental Design: Mutational analysis of DNA from 140 pretreatment tumor biopsies and 8 human cervical cancer cell lines was performed. C33A cells (PIK3CAR88Q and PTENR233*) were treated with increasing concentrations of two allosteric AKT inhibitors (SC-66 and MK-2206) with or without the glucose analogue 2-deoxyglucose (2-DG). Cell viability and activation status of the AKT/mTOR pathway were determined in response to the treatment. Glucose uptake was evaluated by incubation with 18F-fluorodeoxyglucose (FDG). Cell migration was assessed by scratch assay.

Results: Activating PIK3CA (E545K, E542K) and inactivating PTEN (R233*) mutations were identified in human cervical cancer. SC-66 effectively inhibited AKT, mTOR and mTOR substrates in C33A cells. SC-66 inhibited glucose uptake via reduced delivery of Glut1 and Glut4 to the cell membrane. SC-66 (1 µg/ml-56%) and MK-2206 (30 µM-49%) treatment decreased cell viability through a non-apoptotic mechanism. Decreases in cell viability were enhanced when AKT inhibitors were combined with 2-DG. The scratch assay showed a substantial reduction in cell migration upon SC-66 treatment.

Conclusions: The mutational spectrum of the PI3K/AKT pathway in cervical cancer is complex. AKT inhibitors effectively block mTORC1/2, decrease glucose uptake, glycolysis, and decrease cell viability in vitro. These results suggest that AKT inhibitors may improve response to chemoradiation in cervical cancer.

Citing Articles

The effects of hydrotherapy and cryotherapy on recovery from acute post-exercise induced muscle damage-a network meta-analysis.

Chen R, Ma X, Ma X, Cui C BMC Musculoskelet Disord. 2024; 25(1):749.

PMID: 39294614 PMC: 11409518. DOI: 10.1186/s12891-024-07315-2.

Phytochemical analysis, and study of antiproliferative activity of ethyl acetate fraction of (Hochst. ex Oliv. & Hiern) C. Jeffrey against human cervical cancer cell line.

Lagu I, Nyamai D, Njeru S Front Pharmacol. 2024; 15:1399885.

PMID: 39005932 PMC: 11239972. DOI: 10.3389/fphar.2024.1399885.

Anticancer Effects of Mitoquinone via Cell Cycle Arrest and Apoptosis in Canine Mammary Gland Tumor Cells.

Lee R, Lee W, Park H Int J Mol Sci. 2024; 25(9).

PMID: 38732133 PMC: 11084895. DOI: 10.3390/ijms25094923.

Genetic Characterization of Ovarian Tumor Tissues from Patients with Epithelial Ovarian Cancer in a Philippine Tertiary Hospital: A Descriptive Study.

Lintao R, Padua A, Nakura Y, Llamas-Clark E, Yanagihara I Asian Pac J Cancer Prev. 2023; 24(4):1187-1197.

PMID: 37116140 PMC: 10352754. DOI: 10.31557/APJCP.2023.24.4.1187.

Quantitative proteomics identified a novel invasion biomarker associated with EMT in pituitary adenomas.

Zhang Y, Li L, Ma X, Liu C, Liu G, Bie Z Front Endocrinol (Lausanne). 2023; 14:1137648.

PMID: 36936141 PMC: 10020714. DOI: 10.3389/fendo.2023.1137648.

References

Alessi D, Deak M, Casamayor A, Caudwell F, Morrice N, Norman D . 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol. 1997; 7(10):776-89. DOI: 10.1016/s0960-9822(06)00336-8. View

McIntyre J, Wu J, Craighead P, Phan T, Kobel M, Lees-Miller S . PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2012; 128(3):409-14. DOI: 10.1016/j.ygyno.2012.12.019. View

Pang H, Flinn R, Patsialou A, Wyckoff J, Roussos E, Wu H . Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 2009; 69(23):8868-76. PMC: 2793177. DOI: 10.1158/0008-5472.CAN-09-1968. View

Isakoff S, Engelman J, Irie H, Luo J, Brachmann S, Pearline R . Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005; 65(23):10992-1000. DOI: 10.1158/0008-5472.CAN-05-2612. View

Currie R, Walker K, Gray A, Deak M, Casamayor A, Downes C . Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J. 1999; 337 ( Pt 3):575-83. PMC: 1220012. View

Zeng Z, Sarbassov D, Samudio I, Yee K, Munsell M, Ellen Jackson C . Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2006; 109(8):3509-12. PMC: 1852241. DOI: 10.1182/blood-2006-06-030833. View

Han S, Kato H, Kato S, Suzuki T, Shibata H, Ishii S . Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res. 2000; 60(12):3147-51. View

Rodrik-Outmezguine V, Chandarlapaty S, Pagano N, Poulikakos P, Scaltriti M, Moskatel E . mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011; 1(3):248-59. PMC: 3227125. DOI: 10.1158/2159-8290.CD-11-0085. View

She Q, Chandarlapaty S, Ye Q, Lobo J, Haskell K, Leander K . Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One. 2008; 3(8):e3065. PMC: 2516933. DOI: 10.1371/journal.pone.0003065. View

10.

Macconaill L, Campbell C, Kehoe S, Bass A, Hatton C, Niu L . Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009; 4(11):e7887. PMC: 2774511. DOI: 10.1371/journal.pone.0007887. View

11.

Serra V, Markman B, Scaltriti M, Eichhorn P, Valero V, Guzman M . NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008; 68(19):8022-30. DOI: 10.1158/0008-5472.CAN-08-1385. View

12.

Manning B, Cantley L . AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-74. PMC: 2756685. DOI: 10.1016/j.cell.2007.06.009. View

13.

Simons A, Ahmad I, Mattson D, Dornfeld K, Spitz D . 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007; 67(7):3364-70. PMC: 3852417. DOI: 10.1158/0008-5472.CAN-06-3717. View

14.

Gonzalez E, McGraw T . The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle. 2009; 8(16):2502-8. PMC: 2997486. DOI: 10.4161/cc.8.16.9335. View

15.

Schwarz J, Siegel B, Dehdashti F, Grigsby P . Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA. 2007; 298(19):2289-95. DOI: 10.1001/jama.298.19.2289. View

16.

Larue L, Bellacosa A . Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24(50):7443-54. DOI: 10.1038/sj.onc.1209091. View

17.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

18.

Majumder P, Sellers W . Akt-regulated pathways in prostate cancer. Oncogene. 2005; 24(50):7465-74. DOI: 10.1038/sj.onc.1209096. View

19.

Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K . PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008; 68(19):8127-36. DOI: 10.1158/0008-5472.CAN-08-0755. View

20.

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View